ReviewPharmaceutics2021
Strategies for Vaccination: Conventional Vaccine Approaches Versus New-Generation Strategies in Combination with Adjuvants.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 75 citations in OpenAlex.
- Immunoinformatics-driven multi-epitope vaccine design as a promising strategy against multidrug-resistant pathogens: a comprehensive review.Folia microbiologica · 2026Review
- Cooperative supramolecular integration of QS-21 into polymeric micelles as a tunable nanoadjuvant platform for subunit vaccines.RSC advances · 2026Article
- Article
- Design of a global population-covering multi-epitope mRNA vaccine against Lassa virus using immunoinformatics.Scientific reports · 2026Article
- Exosome-based vaccines in cancer immunotherapy: antitumor mechanisms, engineering strategies, and challenges.Journal of cancer research and clinical oncology · 2026Review
- Article
- Extracellular vesicles as vaccine platforms: emerging opportunities for malaria.Frontiers in immunology · 2026Review
- A Comprehensive Review of Vaccine Development: From Traditional Platforms to Messenger RNA (mRNA) Technologies.Cureus · 2026Review
- Edible Vaccines: A Paradigm Shift in Vaccine Delivery and Global Health Solutions.Current drug discovery technologies · 2026Review
- Multi-Epitope-Based Peptide Vaccine Against Bovine Parainfluenza Virus Type 3: Design and Immunoinformatics Approach.Veterinary sciences · 2025Article
- Antiviral Inactivated Vaccines: Looking to the Past to Face the Future-A Narrative Review.Vaccines · 2025Review
- Facile Synthesis of Lecithin-Sophorolipid Liponiosomes Encapsulating SARS-CoV‑2 Proteins for Therapeutic Applications.ACS omega · 2025Article
- Membrane Expression Enhances Folding, Multimeric Structure Formation, and Immunogenicity of Viral Capsid Proteins.ACS infectious diseases · 2025Article
- Review
- From genetic code to global health: the impact of nucleic acid vaccines on disease prevention and treatment.RSC medicinal chemistry · 2025Review
- Virus-like Particles-based Vaccine to Combat Neurodegenerative Diseases.Current pharmaceutical biotechnology · 2025Review
- Immunoinformatics-Aided Design of a Multiepitope Vaccine AgainstBioinformatics and biology insights · 2025Article
- mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy.Frontiers in bioengineering and biotechnology · 2025Review
- Designing and comparative analysis of anti-oxidant and heat shock proteins based multi-epitopic filarial vaccines.BMC infectious diseases · 2024Article
- Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.Vaccine: X · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
The current COVID-19 pandemic, caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), has raised significant economic, social, and psychological concerns. The rapid spread of the virus, coupled with the absence of vaccines and antiviral treatments for SARS-CoV-2, has galvanized a major global endeavor to develop effective vaccines. Within a matter of just a few months of the initial outbreak, research teams worldwide, adopting a range of different strategies, embarked on a quest to develop effective vaccine that could be effectively used to suppress this virulent pathogen. In this review, we describe conventional approaches to vaccine development, including strategies employing proteins, peptides, and attenuated or inactivated pathogens in combination with adjuvants (including genetic adjuvants). We also present details of the novel strategies that were adopted by different research groups to successfully transfer recombinantly expressed antigens while using viral vectors (adenoviral and retroviral) and non-viral delivery systems, and how recently developed methods have been applied in order to produce vaccines that are based on mRNA, self-amplifying RNA (saRNA), and trans-amplifying RNA (taRNA). Moreover, we discuss the methods that are being used to enhance mRNA stability and protein production, the advantages and disadvantages of different methods, and the challenges that are encountered during the development of effective vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.